SOMNOSYNC

Insights

We are developing a novel screening tool for REM sleep analysis that possesses a unique global selling proposition. This will make it possible, for the first time, to adequately analyze REM sleep behavior disorder (RBD)—even in a home environment. RBD is of particular clinical significance as a potential early stage of neurodegenerative diseases, given that a large proportion of patients with RBD go on to develop Parkinson’s disease or related syndromes over a period of 8 to 15 years. Market launch is scheduled for 2030.